E-CHOP方案治疗20例T细胞性非霍奇金淋巴瘤的疗效分析

E-CHOP Regimen in the Treatment for Non-Hodgkin's Lymphoma(T型)

目的：E-CHOP方案治疗T细胞性非霍奇金淋巴瘤（T-NHL）患者的近期疗效、远期生存和不良反映。方法：回顾性分析20例T-NHL患者的临床特征及E-CHOP方案化疗加或不加局部放疗的近期疗效、不良反应及远期生存情况。结果：20例患者中,平均年龄45岁,临床分期Ⅰ-Ⅱ期3例,占15%;Ⅲ-Ⅳ期占85%,经国际预后指数（IPI）评分为3-4分者占85%,此20例患者均采用E-CHOP方案治疗,平均6-9个疗程,加或不加局部放疗,评价客观疗效,总有效率为74.3%,CR率为55%。主要不良反应为骨髓抑制;平均随访期为27个月（6-48个月）,1-4年生存率分别为：60%、50%、40%、35%。结论：采用E-CHOP方案治疗T-NHL近期疗效、远期生存率较以往有提高,副作用少,价格低廉,值得临床进一步验证和推广应用。

Objective： The aim of this study is to analyse the efficacy and toxicity of E - CHOP regimen the treatment of non-Hodgkin＇s lymphoma（T- NHL）. Methods：from may 2003 to may 2007, 20patients with T - NHL , were treated by E - chop regiment with or without radiotherapy for the involved field. The dinical cha racteristics, response, toxicity and long- term survival results were analysed retrospectively. Results：The median age was 45 （range： 18 - 62 y）, All patients were treated by E - CHOP 6 -- 9, with or without radiotherapy. The overall response（OR）rate in this series was 74.3 %, with a complete remission（ CR） rate of 55 %. major toxicity consisted of grade Ⅲ-Ⅳ myelosuppression （ 10 % ）, neutropenia （ 35 ）, and thrombocytopenia and anema （ 1.3 % ）, median follow - up duration in this series was 27 months （range： 6 -48 months）, the overall 1 -- 4 year survival rate was： 60 % ; 50 % ; 40 % ; 35 %. Conclusion： Our data show that E - CHOP regimen combined with or without radiotherapy for the involved field is effective and well to tolerated by the patients with T - NHL.